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Introduction
Hereditary hemochromatosis (HH) is a disorder characterised by increase of serum iron parameters and gradual iron accumulation in parenchymal organs. Since the discovery of the genetic defects of the most common form of hereditary hemochromatosis (HFE, type 1 hemochromatosis), many observations have shown that not only rare/familial mutations in HFE can be present but also that mutations in other genes (transferrin receptor 2, TFR2; hepcidin, HAMP; Hemojuvelin, HJV; and ferroportin, SLC40A1) can lead to rarer genetic forms of iron overload, referred as non-HFE hemochromatosis1. The genetic heterogeneity is particularly evident in the Italian population where only 2/3 of hemochromatosis patients are HFE C282Y homozygotes2, requiring expensive and time-consuming gene specific genotyping to define the molecular diagnosis. Therefore, “second level” genetic tests should be developed for a rapid and simultaneous study of the hemochromatosis genes.
The most common non-HFE hemochromatosis is the autosomal dominant hemochromatosis type 4 (HH4). It is caused by mutations in SLC40A1 gene, encoding for cellular iron exporter ferroportin. Ferroportin acts as receptor of hepcidin, the key regulator of iron metabolism. The hepcidin/ferroportin interaction induces the internalization of the complex, causing a decrease of iron export and its retention in the cell3. HH4 can be phenotypically classified in two groups: patients may have hyperferritinemia with normal/low transferrin saturation (type-A HH4, ferroportin disease) or both serum iron parameters increased (type-B HH4, non-classical ferroportin disease)4. This depends on ferroportin impairment that could be classified as “loss-of-function” or “gain-of-function”. In the first case (type-A) the mutated protein is not expressed on the membrane and it is not able to exert its exporting function. In the second case (type-B), the mutated iron exporter becomes resistant to the activity of hepcidin, causing increased iron absorption. Several mutations have been characterized in HH4 patients, spreading along the entire gene sequence4. The position of the correspondent aminoacidic change is important to define the HH4 clinical phenotype5.
Among the different ferroportin mutations, the p.A69T variant, despite the causal nucleotide change not being annotated in dbSNP, has been described in a 52-year-old Italian woman with diabetes and type-B HH4, on the basis of hepatocyte iron overload6, but no iron parameters and clinical history of the patient were described. The pathogenic role of this mutation has been subsequently confirmed through in-vitro experiments in which mutant cDNA has been overexpressed7. These studies demonstrated that p.A69T mutated ferroportin has a partial resistance to hepcidin.
Here we report an Italian patient with a severe iron overload phenotype in which a careful clinical characterization led to diagnose a p.A69T non-classical ferroportin disease through the combination of capture of technology with next generation sequencing (NGS) platform.

Case report.
In April 2012, a 47-years-old man came to the attention of the Department of Transfusion Medicine in Turin for hepatopathy of unknown origin with biochemical signs of iron-overload. There was a familial history of chronic liver disease since the father died of cirrhosis of unknown origins. The patient had severe hyperferritinemia (6242 ng/mL), elevated transferrin saturation (95.4%), elevated transaminase levels, increased liver echogenicity mimicking “steatosis” with signs of progression to liver fibrosis at elastography evaluation (9 kPa, F2 Metavir Scale), splenomegaly and arthritis. Red blood cell indices were normal (RBC 5.12 million/μl, Hb 144 g/L, MCV 87 fL). Viral hepatitis and inflammatory diseases were excluded. There were neither endocrine nor cardiac dysfunctions. DNA from mononuclear peripheral blood cells was prepared by standard protocols and a reverse-hybridization assay (Haemochromatosis StripAssay, Nuclear Laser, Settala, Milan, Italy) was used for the simultaneous detection of 10 HFE gene mutations (V53M, V59M, H63D, H63H, S65C, E168X, E168Q, W169X, C282Y, Q283P), 3 TFR2 mutations (Y250X, E60X, M172K) and 2 SLC40A1/ferroportin mutations (N144H, V162del). This first level genetic test showed that the patient was heterozygous for the HFE p.H63D polymorphism. 
A weekly phlebotomy treatment was started and well tolerated; no decrease of Hb was seen. After 9 months, despite a 12-weeks combined chelation therapy with deferoxamine, ferritin levels were persistently high (6519 ng/mL). To accelerate iron depletion phlebotomies were replaced by erythro-apheresis. One month later ferritin declined (3431 ng/mL) and serum hepcidin (Hep-25), measured by SELDI-TOF-MS8, was 10.2 nM (normal range 7.02-10.05 9). In the following 16 months, ferritin and transaminases level gradually decreased. Overall, 21 g of iron were removed before iron depletion. Subsequently, monthly phlebotomies were planned as maintenance therapy (Figure 1). During maintenance therapy (Ferritin 94 ng/mL) serum hepcidin was lower than normal (0.55 nM).
Due to the genetically unexplained hemochromatosis phenotype, a second level genetic test10 was performed by combining capture of the five HH genes (HFE, HFE2, TFR2, SLC40A1/ferroportin, and HAMP/hepcidin) through HaloPlexTM Technology (Agilent Technologies, Santa Clara CA) and sequencing by the IlluminaHiSeq 1000 platform (Illumina, San Diego CA). Sequence reads were aligned against human reference HG19, and analyzed by GoldenHelix™ software to detect all the possible pathogenetic variants. In addition to the known heterozygote p.H63D variant, a C>T change in exon 3 of the ferroportin/SLC40A1 gene at position 190439953 of chromosome 2 (GRCh37/HG19) was identified, leading to the substitution of threonine for alanine at position 69 (p.A69T). The presence of the p.A69T mutation was confirmed by direct sequencing of an amplicon in ferroportin exon 3 using ABI Prism 3130 xl Genetic Analyzer (Applied Biosystem) with the following primers (Fpn1F: 5’CTTCCTGAGTACAATAGACTAG3’, Fpn1R: 5’CAGAGGTAGCTCAGGCAT3’). GOR IV Secondary Structure prediction server (http://mig.jouy.inra.fr) was used to predict in-silico whether the aminoacid change would interfere with ferroportin structure. This analysis revealed that the substitution causes profound modifications in protein structure (Figure 2A). The mutation was not found in the probands’ mother and sister (Figure 2B), that had normal iron parameter and serum Hep-25 slightly decreased.

Discussion
A total of five hemochromatosis genes and several different mutations, some of which can be very rare or even private familial variants, have been characterized since the discovery of HFE1. Therefore, especially in populations in which inherited iron overloaded disorders are not genetically homogeneous2, genetic diagnosis can be difficult and traditional approach based on single mutation detection and sequencing of candidate genes can be unsuccessful or expensive and time consuming.
Large-scale analysis based on massively parallel DNA-sequencing systems has recently overcome this problem. Moreover, hybridization-based capture and PCR-based amplification of targeted sequence followed by NGS allows one to study only the genomic regions of interest making the genetic analysis cost-effective. The latter approach has been successfully used to identify causal mutations in many Mendelian and complex neurological conditions11, in primary immunodeficiencies12 and to screen for recurrently mutated genes in chronic lymphocytic leukemia13. Moreover, NGS approaches have been recently advocated to identify rare hemochromatosis variants when iron overload is well documented and initial screening approaches negative14.
In this study we performed a HaloPlex™ capture with NGS platform analysis to screen simultaneously 5 hemochromatosis genes in a patient with a clear hemochromatosis phenotype (on the basis of age of onset, high serum ferritin, high transferrin saturation and hepatopathy) but without genetic diagnosis. Our approach allowed identifying a rare mutation (p.A69T) in ferroportin gene that had led to a type B HH4, a non-classical ferroportin disease. The patient’s phenotype is in accordance with the “gain-of-function” of p.A69T mutant ferroportin, recently described as partially resistant to hepcidin in-vitro7. Concordantly, and in contrast with the most types of hemochromatosis, no hepcidin deficiency was seen in our iron overloaded patient (despite phlebotomy/erythro-apheresis treatment was ongoing). Few studies have assessed the serum hepcidin level in hemochromatosis due to ferroportin mutations. In two reports it has been shown that patients carrying ferroportin variants (either abolishing hepcidin binding to ferroportin15, or leading to classical ferroportin disease16) have high serum hepcidin. These and our data confirm that the cause for HH4 is not a hepcidin deficiency as in other types of hemochromatosis (related to HFE17, TFR218 or HJV19 mutations) but the lack of functional ferroportin. However, once an iron depletion state was achieved and a monthly phlebotomy maintenance treatment started, a decrease of hepcidin concentration was seen, as already demonstrated in other hemochromatosis types20. This might be related to a regulatory effect by depleted iron stores and/or by stimulated erythropoiesis in response to long-term phlebotomy treatment.
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Decline of ferritin concentration during the iron removal treatments. Phlebotomy was carried out by removing about 400 ml of blood. Asterisks indicate the serum Hepc dosage points (* Hep25=10.2 nM; ** Hep25=0.55 nM).

Figure 2 
(A) Secondary structure prediction of p.A69T mutated Ferroportin protein according to GOR IV server (http://mig.jouy.inra.fr). Double-headed arrow points to the loss of n alpha-helix motif. Percentage of main aminoacidic motifs are reported on the right, altered values in mutated protein are highlighted in red. (B) On the left, genealogical tree of the patient (II-1). On the right, electrophoretograms of patient antisense sequence, encompassing the C>T genomic mutation (pointed by an arrow), and of the two available relatives.
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